Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03-18

AUTHORS

Peng Yuan, Jianzhong Shentu, Jianming Xu, Wendy Burke, Kate Hsu, Maria Learoyd, Min Zhu, Binghe Xu

ABSTRACT

PURPOSE: Chinese patients have been enrolled in multiple Phase III trials of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza); however, the pharmacokinetic (PK) profile of olaparib has not been investigated in this population. This two-part, open-label Phase I study was, therefore, carried out to determine the PK and safety profile of olaparib (tablet formulation) in Chinese patients with advanced solid tumours as monotherapy and in combination with paclitaxel (NCT02430311). METHODS: The PK profile of olaparib 300 mg (twice daily [bid]; Cohort 1) as monotherapy after a single dose and at steady state, and 100 mg (bid; Cohort 2) as monotherapy (single dose and at steady state) and in combination (at steady state) with weekly paclitaxel (80 mg/m2) was assessed during Part A. Patients could continue to receive treatment (monotherapy, Cohort 1; combination therapy, Cohort 2) in Part B, which assessed safety and tolerability. RESULTS: Twenty and 16 patients were enrolled into Cohorts 1 and 2, respectively. Steady-state olaparib exposure increased slightly less than proportionally with increasing monotherapy dose and inter-patient variability was high. A statistically significant decrease in olaparib exposure was seen when given in combination with paclitaxel. Discontinuation due to adverse events (AEs) was rare and haematological AEs were more common in patients receiving combination treatment. CONCLUSIONS: The PK and safety profile of olaparib monotherapy in Chinese patients is consistent with that seen previously in Western and Japanese patients, and the recommended Phase III monotherapy tablet dose (300 mg bid) is suitable for use in this population. More... »

PAGES

1-12

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-019-03799-1

DOI

http://dx.doi.org/10.1007/s00280-019-03799-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112853003

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30887180


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Tsinghua University", 
          "id": "https://www.grid.ac/institutes/grid.12527.33", 
          "name": [
            "National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No. 17 Panjiayuan, Chaoyang District, 100021, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yuan", 
        "givenName": "Peng", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Affiliated Hospital Zhejiang University", 
          "id": "https://www.grid.ac/institutes/grid.452661.2", 
          "name": [
            "Research Center for Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital of Zhejiang University, Zhejiang, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shentu", 
        "givenName": "Jianzhong", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Academy of Military Medical Sciences", 
          "id": "https://www.grid.ac/institutes/grid.410740.6", 
          "name": [
            "Affiliated Hospital Cancer Center, The 307th Hospital of Chinese People\u2019s Liberation Army, Academy of Military Medical Sciences, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xu", 
        "givenName": "Jianming", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Covance Clinical Research Unit, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burke", 
        "givenName": "Wendy", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "AstraZeneca, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hsu", 
        "givenName": "Kate", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Cambridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Learoyd", 
        "givenName": "Maria", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "AstraZeneca, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhu", 
        "givenName": "Min", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tsinghua University", 
          "id": "https://www.grid.ac/institutes/grid.12527.33", 
          "name": [
            "National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No. 17 Panjiayuan, Chaoyang District, 100021, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xu", 
        "givenName": "Binghe", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2014.60.0320", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002205745"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-015-0214-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003999941", 
          "https://doi.org/10.1007/s12325-015-0214-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-015-0214-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003999941", 
          "https://doi.org/10.1007/s12325-015-0214-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jep.2013.07.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005159115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-05-1186", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007563264"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.20017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009812203"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.0806092105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012304925"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6604851", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013560743", 
          "https://doi.org/10.1038/sj.bjc.6604851"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/00498254.2016.1241449", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015964937"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2016.08.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018585095"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2016.08.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018585095"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.31.5.681", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020624624"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-07-4953", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024438057"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.2008.141", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024517567", 
          "https://doi.org/10.1038/clpt.2008.141"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.pharmthera.2012.12.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026929795"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-016-3106-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036246857", 
          "https://doi.org/10.1007/s00280-016-3106-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-016-3106-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036246857", 
          "https://doi.org/10.1007/s00280-016-3106-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/bcr3484", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040423249", 
          "https://doi.org/10.1186/bcr3484"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-015-2836-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043821500", 
          "https://doi.org/10.1007/s00280-015-2836-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11523-016-0435-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049466672", 
          "https://doi.org/10.1007/s11523-016-0435-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049886783"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu327.76", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083556229"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1706450", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085864115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/00498254.2017.1346332", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090390050"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30469-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090898407"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30469-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090898407"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30682-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092517534"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cpt.1103", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103748222"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.34.15_suppl.2562", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106841509"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.35.15_suppl.tps5091", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106850126"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0714-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107820621", 
          "https://doi.org/10.1007/s40262-018-0714-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0714-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107820621", 
          "https://doi.org/10.1007/s40262-018-0714-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0714-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107820621", 
          "https://doi.org/10.1007/s40262-018-0714-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0714-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107820621", 
          "https://doi.org/10.1007/s40262-018-0714-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.32.15_suppl.tps5616", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111109886"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03-18", 
    "datePublishedReg": "2019-03-18", 
    "description": "PURPOSE: Chinese patients have been enrolled in multiple Phase III trials of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza); however, the pharmacokinetic (PK) profile of olaparib has not been investigated in this population. This two-part, open-label Phase I study was, therefore, carried out to determine the PK and safety profile of olaparib (tablet formulation) in Chinese patients with advanced solid tumours as monotherapy and in combination with paclitaxel (NCT02430311).\nMETHODS: The PK profile of olaparib 300\u00a0mg (twice daily [bid]; Cohort 1) as monotherapy after a single dose and at steady state, and 100\u00a0mg (bid; Cohort 2) as monotherapy (single dose and at steady state) and in combination (at steady state) with weekly paclitaxel (80\u00a0mg/m2) was assessed during Part\u00a0A. Patients could continue to receive treatment (monotherapy, Cohort 1; combination therapy, Cohort 2) in Part\u00a0B, which assessed safety and tolerability.\nRESULTS: Twenty and 16 patients were enrolled into Cohorts 1 and 2, respectively. Steady-state olaparib exposure increased slightly less than proportionally with increasing monotherapy dose and inter-patient variability was high. A statistically significant decrease in olaparib exposure was seen when given in combination with paclitaxel. Discontinuation due to adverse events (AEs) was rare and haematological AEs were more common in patients receiving combination treatment.\nCONCLUSIONS: The PK and safety profile of olaparib monotherapy in Chinese patients is consistent with that seen previously in Western and Japanese patients, and the recommended Phase III monotherapy tablet dose (300\u00a0mg bid) is suitable for use in this population.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-019-03799-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "83"
      }
    ], 
    "name": "Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours", 
    "pagination": "1-12", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-019-03799-1"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "5d85e9de9898d1f12580177783623806d959eb3e5ca4ec6fde7c55f96b5bf479"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112853003"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30887180"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-019-03799-1", 
      "https://app.dimensions.ai/details/publication/pub.1112853003"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000376_0000000376/records_56173_00000006.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00280-019-03799-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03799-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03799-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03799-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03799-1'


 

This table displays all metadata directly associated to this object as RDF triples.

217 TRIPLES      21 PREDICATES      56 URIs      20 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-019-03799-1 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N369e49ed710a4abd82147bbcc75925d6
4 schema:citation sg:pub.10.1007/s00280-015-2836-2
5 sg:pub.10.1007/s00280-016-3106-7
6 sg:pub.10.1007/s11523-016-0435-8
7 sg:pub.10.1007/s12325-015-0214-4
8 sg:pub.10.1007/s40262-018-0714-x
9 sg:pub.10.1038/clpt.2008.141
10 sg:pub.10.1038/sj.bjc.6604851
11 sg:pub.10.1186/bcr3484
12 https://doi.org/10.1002/cpt.1103
13 https://doi.org/10.1002/jps.20017
14 https://doi.org/10.1016/j.clinthera.2016.08.010
15 https://doi.org/10.1016/j.jep.2013.07.014
16 https://doi.org/10.1016/j.pharmthera.2012.12.007
17 https://doi.org/10.1016/s1470-2045(17)30469-2
18 https://doi.org/10.1016/s1470-2045(17)30682-4
19 https://doi.org/10.1056/nejmoa1706450
20 https://doi.org/10.1073/pnas.0806092105
21 https://doi.org/10.1080/00498254.2016.1241449
22 https://doi.org/10.1080/00498254.2017.1346332
23 https://doi.org/10.1093/annonc/mdu187
24 https://doi.org/10.1093/annonc/mdu327.76
25 https://doi.org/10.1124/dmd.31.5.681
26 https://doi.org/10.1158/0008-5472.can-05-1186
27 https://doi.org/10.1158/1078-0432.ccr-07-4953
28 https://doi.org/10.1200/jco.2014.32.15_suppl.tps5616
29 https://doi.org/10.1200/jco.2014.60.0320
30 https://doi.org/10.1200/jco.2016.34.15_suppl.2562
31 https://doi.org/10.1200/jco.2017.35.15_suppl.tps5091
32 schema:datePublished 2019-03-18
33 schema:datePublishedReg 2019-03-18
34 schema:description PURPOSE: Chinese patients have been enrolled in multiple Phase III trials of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza); however, the pharmacokinetic (PK) profile of olaparib has not been investigated in this population. This two-part, open-label Phase I study was, therefore, carried out to determine the PK and safety profile of olaparib (tablet formulation) in Chinese patients with advanced solid tumours as monotherapy and in combination with paclitaxel (NCT02430311). METHODS: The PK profile of olaparib 300 mg (twice daily [bid]; Cohort 1) as monotherapy after a single dose and at steady state, and 100 mg (bid; Cohort 2) as monotherapy (single dose and at steady state) and in combination (at steady state) with weekly paclitaxel (80 mg/m2) was assessed during Part A. Patients could continue to receive treatment (monotherapy, Cohort 1; combination therapy, Cohort 2) in Part B, which assessed safety and tolerability. RESULTS: Twenty and 16 patients were enrolled into Cohorts 1 and 2, respectively. Steady-state olaparib exposure increased slightly less than proportionally with increasing monotherapy dose and inter-patient variability was high. A statistically significant decrease in olaparib exposure was seen when given in combination with paclitaxel. Discontinuation due to adverse events (AEs) was rare and haematological AEs were more common in patients receiving combination treatment. CONCLUSIONS: The PK and safety profile of olaparib monotherapy in Chinese patients is consistent with that seen previously in Western and Japanese patients, and the recommended Phase III monotherapy tablet dose (300 mg bid) is suitable for use in this population.
35 schema:genre research_article
36 schema:inLanguage en
37 schema:isAccessibleForFree false
38 schema:isPartOf N57a536e7f6fb4d7cbad14d72eebdb144
39 N5c18ae05746a4ed3a9e357b98e00a9e2
40 sg:journal.1088364
41 schema:name Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours
42 schema:pagination 1-12
43 schema:productId N293af4ec8efe4dfea9f7eaea126cfc31
44 N4596ff1896cc4bf1bed407d13238bec7
45 N4aba13a51d744ec09350218421b81bf3
46 N7fcc1374441c4e4299a898c9287eb9dc
47 Na2c05e7b37e94ba9a81295a236fe473b
48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112853003
49 https://doi.org/10.1007/s00280-019-03799-1
50 schema:sdDatePublished 2019-04-15T09:18
51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
52 schema:sdPublisher N83b241219d504c78959f0d7f5f2c33c4
53 schema:url https://link.springer.com/10.1007%2Fs00280-019-03799-1
54 sgo:license sg:explorer/license/
55 sgo:sdDataset articles
56 rdf:type schema:ScholarlyArticle
57 N0e662c9cda5943c89bc6eb76069badcc schema:affiliation https://www.grid.ac/institutes/grid.410740.6
58 schema:familyName Xu
59 schema:givenName Jianming
60 rdf:type schema:Person
61 N293af4ec8efe4dfea9f7eaea126cfc31 schema:name dimensions_id
62 schema:value pub.1112853003
63 rdf:type schema:PropertyValue
64 N2f6ebdbac4dd4874b9b6bba2e2345dd7 schema:affiliation Nbb344559140d44e49865c7e02b1f5f02
65 schema:familyName Burke
66 schema:givenName Wendy
67 rdf:type schema:Person
68 N33ea9f8ddfd84520ba86233cc3ce5108 rdf:first N0e662c9cda5943c89bc6eb76069badcc
69 rdf:rest N6c52f5eff87e4d86a8e3cda92c034256
70 N3475ee4ff330418dbb6033f7e72ae656 rdf:first N3ee9215ea22a4127acb99960ad364df5
71 rdf:rest N759a23b983f4485ea3408c55cc7a5a2c
72 N3579f2fc4f80486fafc40110263bfa23 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
73 schema:familyName Learoyd
74 schema:givenName Maria
75 rdf:type schema:Person
76 N369e49ed710a4abd82147bbcc75925d6 rdf:first N74d86244de184ee1bbccba7b3b0eda50
77 rdf:rest Nff30e0139ea0424fbb9d9fbfd5a0f563
78 N3dc2c31de13e4a3683a2396a589c048c schema:affiliation https://www.grid.ac/institutes/grid.452661.2
79 schema:familyName Shentu
80 schema:givenName Jianzhong
81 rdf:type schema:Person
82 N3ee9215ea22a4127acb99960ad364df5 schema:affiliation Ne38559e3b5884a1c8089cbd0e31f49fe
83 schema:familyName Hsu
84 schema:givenName Kate
85 rdf:type schema:Person
86 N4596ff1896cc4bf1bed407d13238bec7 schema:name nlm_unique_id
87 schema:value 7806519
88 rdf:type schema:PropertyValue
89 N4aba13a51d744ec09350218421b81bf3 schema:name doi
90 schema:value 10.1007/s00280-019-03799-1
91 rdf:type schema:PropertyValue
92 N57a536e7f6fb4d7cbad14d72eebdb144 schema:volumeNumber 83
93 rdf:type schema:PublicationVolume
94 N5c18ae05746a4ed3a9e357b98e00a9e2 schema:issueNumber 5
95 rdf:type schema:PublicationIssue
96 N61ff3a62a859432f808e6c46bfcf2914 schema:name AstraZeneca, Shanghai, China
97 rdf:type schema:Organization
98 N6c52f5eff87e4d86a8e3cda92c034256 rdf:first N2f6ebdbac4dd4874b9b6bba2e2345dd7
99 rdf:rest N3475ee4ff330418dbb6033f7e72ae656
100 N6f602d2f41bc4b9aaf6b89d62520ca2a rdf:first Nacf700d147cd4286acd5e280cf2c6419
101 rdf:rest N760dda8d2a124de789ea65edffdf48c9
102 N74d86244de184ee1bbccba7b3b0eda50 schema:affiliation https://www.grid.ac/institutes/grid.12527.33
103 schema:familyName Yuan
104 schema:givenName Peng
105 rdf:type schema:Person
106 N759a23b983f4485ea3408c55cc7a5a2c rdf:first N3579f2fc4f80486fafc40110263bfa23
107 rdf:rest N6f602d2f41bc4b9aaf6b89d62520ca2a
108 N760dda8d2a124de789ea65edffdf48c9 rdf:first Nee6cee4f8c494f029e9210f0697e59da
109 rdf:rest rdf:nil
110 N7fcc1374441c4e4299a898c9287eb9dc schema:name readcube_id
111 schema:value 5d85e9de9898d1f12580177783623806d959eb3e5ca4ec6fde7c55f96b5bf479
112 rdf:type schema:PropertyValue
113 N83b241219d504c78959f0d7f5f2c33c4 schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 Na2c05e7b37e94ba9a81295a236fe473b schema:name pubmed_id
116 schema:value 30887180
117 rdf:type schema:PropertyValue
118 Nacf700d147cd4286acd5e280cf2c6419 schema:affiliation N61ff3a62a859432f808e6c46bfcf2914
119 schema:familyName Zhu
120 schema:givenName Min
121 rdf:type schema:Person
122 Nbb344559140d44e49865c7e02b1f5f02 schema:name Covance Clinical Research Unit, Leeds, UK
123 rdf:type schema:Organization
124 Ne38559e3b5884a1c8089cbd0e31f49fe schema:name AstraZeneca, Shanghai, China
125 rdf:type schema:Organization
126 Nee6cee4f8c494f029e9210f0697e59da schema:affiliation https://www.grid.ac/institutes/grid.12527.33
127 schema:familyName Xu
128 schema:givenName Binghe
129 rdf:type schema:Person
130 Nff30e0139ea0424fbb9d9fbfd5a0f563 rdf:first N3dc2c31de13e4a3683a2396a589c048c
131 rdf:rest N33ea9f8ddfd84520ba86233cc3ce5108
132 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
133 schema:name Medical and Health Sciences
134 rdf:type schema:DefinedTerm
135 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
136 schema:name Clinical Sciences
137 rdf:type schema:DefinedTerm
138 sg:journal.1088364 schema:issn 0344-5704
139 1432-0843
140 schema:name Cancer Chemotherapy and Pharmacology
141 rdf:type schema:Periodical
142 sg:pub.10.1007/s00280-015-2836-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043821500
143 https://doi.org/10.1007/s00280-015-2836-2
144 rdf:type schema:CreativeWork
145 sg:pub.10.1007/s00280-016-3106-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036246857
146 https://doi.org/10.1007/s00280-016-3106-7
147 rdf:type schema:CreativeWork
148 sg:pub.10.1007/s11523-016-0435-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049466672
149 https://doi.org/10.1007/s11523-016-0435-8
150 rdf:type schema:CreativeWork
151 sg:pub.10.1007/s12325-015-0214-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003999941
152 https://doi.org/10.1007/s12325-015-0214-4
153 rdf:type schema:CreativeWork
154 sg:pub.10.1007/s40262-018-0714-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1107820621
155 https://doi.org/10.1007/s40262-018-0714-x
156 rdf:type schema:CreativeWork
157 sg:pub.10.1038/clpt.2008.141 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024517567
158 https://doi.org/10.1038/clpt.2008.141
159 rdf:type schema:CreativeWork
160 sg:pub.10.1038/sj.bjc.6604851 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013560743
161 https://doi.org/10.1038/sj.bjc.6604851
162 rdf:type schema:CreativeWork
163 sg:pub.10.1186/bcr3484 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040423249
164 https://doi.org/10.1186/bcr3484
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1002/cpt.1103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103748222
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1002/jps.20017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009812203
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1016/j.clinthera.2016.08.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018585095
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1016/j.jep.2013.07.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005159115
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/j.pharmthera.2012.12.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026929795
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1016/s1470-2045(17)30469-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090898407
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1016/s1470-2045(17)30682-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092517534
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1056/nejmoa1706450 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085864115
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1073/pnas.0806092105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012304925
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1080/00498254.2016.1241449 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015964937
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1080/00498254.2017.1346332 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090390050
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1093/annonc/mdu187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049886783
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1093/annonc/mdu327.76 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083556229
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1124/dmd.31.5.681 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020624624
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1158/0008-5472.can-05-1186 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007563264
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1158/1078-0432.ccr-07-4953 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024438057
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1200/jco.2014.32.15_suppl.tps5616 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111109886
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1200/jco.2014.60.0320 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002205745
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1200/jco.2016.34.15_suppl.2562 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106841509
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1200/jco.2017.35.15_suppl.tps5091 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106850126
205 rdf:type schema:CreativeWork
206 https://www.grid.ac/institutes/grid.12527.33 schema:alternateName Tsinghua University
207 schema:name National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No. 17 Panjiayuan, Chaoyang District, 100021, Beijing, China
208 rdf:type schema:Organization
209 https://www.grid.ac/institutes/grid.410740.6 schema:alternateName Academy of Military Medical Sciences
210 schema:name Affiliated Hospital Cancer Center, The 307th Hospital of Chinese People’s Liberation Army, Academy of Military Medical Sciences, Beijing, China
211 rdf:type schema:Organization
212 https://www.grid.ac/institutes/grid.417815.e schema:alternateName AstraZeneca (United Kingdom)
213 schema:name AstraZeneca, Cambridge, UK
214 rdf:type schema:Organization
215 https://www.grid.ac/institutes/grid.452661.2 schema:alternateName First Affiliated Hospital Zhejiang University
216 schema:name Research Center for Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital of Zhejiang University, Zhejiang, China
217 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...